Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Peptide compounds discussed here are not FDA-approved for human use. Do not use injectable compounds without consulting a licensed physician. Consult a qualified healthcare professional before making changes to your diet, exercise, or supplement routine.
Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, Break The Ordinary may earn a small commission at no extra cost to you. I only recommend products I genuinely believe in. See our full disclosure policy.
What Are Peptides? BPC-157, TB-500, and the Science Behind the Most Talked-About Recovery Tools
If you train seriously, you have heard about peptides. What are peptides exactly, and why has every fitness podcast from Huberman Lab to Joe Rogan spent significant time on BPC-157 and TB-500? The short answer: these are short chains of amino acids that function as biological signaling molecules – and a small class of synthetic versions has generated serious interest in sports medicine for their potential role in tissue repair.
The longer answer requires separating the animal-study evidence from human clinical data, understanding what the FDA actually says, and knowing what the WADA ban means for any competitive athlete.
Before going further, it helps to know where peptides fit in the broader picture of recovery. Creatine monohydrate is the most validated recovery supplement in existence – with decades of human clinical data behind it. Natural testosterone optimization through sleep, training, and nutrition is similarly backed by rigorous research.
Sleep quality remains the single most underrated recovery tool available to every man who trains. Peptides, by contrast, are at an earlier stage – promising preclinical data, very thin human evidence, and significant regulatory uncertainty. That gap matters.
Definition: Peptides are short chains of amino acids – typically fewer than 50 – that act as biological signaling molecules, triggering processes like tissue repair, hormone release, and inflammation modulation. They matter because synthetic versions designed to amplify these natural signals have become one of the most discussed and contested tools in sports medicine and biohacking. They are most relevant to men who train seriously and want an evidence-first understanding of what these compounds actually do, what they cannot yet be claimed to do, and where the FDA and WADA actually stand on them in 2026.
Quick Answer: Peptides are short amino acid chains that function as biological messengers in the body. BPC-157 and TB-500 are synthetic peptides studied for tissue repair and recovery. Both have compelling animal-model evidence but virtually no validated human clinical data. Neither is FDA-approved. Both are banned by WADA. As of May 2026, the FDA is actively reviewing whether to permit compounding pharmacies to use them.
Quick Takeaways
- Peptides are amino acid chains – your body already makes thousands naturally.
- BPC-157 and TB-500 are synthetic peptides with mostly animal-study evidence.
- The majority of BPC-157 animal research comes from a single research group.
- Neither compound is FDA-approved or legally sold for human use.
- Both are on the WADA Prohibited List – any competitive athlete is at risk.
- The FDA’s compounding review is scheduled for July 2026 – outcome is unknown.
What Are Peptides, Exactly?
Peptides are short chains of amino acids – the same building blocks that make up proteins. The structural difference is size: a peptide contains fewer than 50 amino acids; a protein contains more. In the body, peptides function as signaling molecules, carrying instructions between cells and triggering biological responses ranging from hormone secretion to inflammation control.
Your body produces thousands of them. Insulin is a peptide. Oxytocin is a peptide.
GLP-1 – the mechanism behind Ozempic – is a peptide. When people ask what are peptides in the context of performance, they are asking about a narrower category: synthetic compounds engineered to exploit these natural signaling pathways. That distinction matters when evaluating fitness community claims.
How Peptides Differ from Proteins and Supplements
Many people assume peptide supplements work the same way as, say, whey protein – that you ingest them and the amino acids get absorbed and used. In fact, the peptides gaining attention in sports medicine – BPC-157 and TB-500 – are not taken orally in the form discussed here. The experimental protocols use subcutaneous injection, because these molecules are too fragile to survive digestion intact in their active form.
The class of peptides relevant to this discussion – synthetic peptides designed to mimic or amplify natural signaling – are not food-derived. BPC-157 is synthesized in a laboratory. It is not extracted from food, not available as a pill with proven bioavailability, and not equivalent to eating protein-rich foods.
Calling it “just amino acids” glosses over the actual pharmacology.
Natural vs. Synthetic Peptides
The body’s own peptides operate within tightly regulated feedback loops. Synthetic peptides are designed to mimic, amplify, or extend those signals – often at concentrations far above what the body would naturally produce. That amplification is the source of both the theoretical benefit and the theoretical risk.
A 2022 review in Signal Transduction and Targeted Therapy – which has accumulated nearly 1,900 citations – confirms that peptide-based drugs are one of the fastest-growing classes in pharmaceutical development, with approved compounds spanning diabetes, HIV, and rare endocrine disorders.
What are peptides, stripped down? Biological messengers. The fitness community is interested in a small set of synthetic versions that appear, in preclinical models, to accelerate tissue repair.
The question worth asking is whether that preclinical signal holds up in humans at any particular dose. The science has not answered that yet.
What Is BPC-157 and What Does the Evidence Actually Say?
BPC-157 – short for Body Protection Compound 157 – is a synthetic 15-amino-acid peptide derived from a protein sequence found in human gastric juice. It does not occur in food. It is not extracted from a natural source.
It is produced in a laboratory, and its use in the fitness and biohacking world is entirely outside any approved clinical framework.
What the Animal Studies Show
The preclinical evidence for BPC-157 is genuinely interesting. To understand what are peptides in this context, BPC-157’s mechanism is a good starting point. A 2020 study in Scientific Reports showed that BPC-157 activates the Src-Caveolin-1-eNOS pathway, increasing endothelial nitric oxide synthase activity and modulating vasomotor tone – the proposed mechanism behind its angiogenic and repair effects.
A 2014 study in Molecules found that BPC-157 enhances growth hormone receptor expression in tendon fibroblasts. A 2015 study in Drug Design, Development and Therapy demonstrated that BPC-157 promoted angiogenesis and cell proliferation in alkali-burn wound models in vivo and in vitro. These are not trivial findings from a mechanistic standpoint.
Consistent angiogenic and tissue-repair signals across multiple study designs give researchers a real reason to pursue human trials. But animal results tell you what a compound does in a controlled rodent model – they do not confirm that the same effect occurs in humans at any particular dose, and they say nothing about safety in people.
The Human Data Problem
A 2026 systematic review in the American Journal of Sports Medicine – authored by researchers at Keck Hospital of USC – examined the full body of evidence for injectable peptides in orthopaedic contexts. Across 36 total studies on BPC-157 for musculoskeletal use, 35 were preclinical and one was a single small human case series.
That one human case series reported pain improvements in knee injection patients but had, in the review authors’ own words, “significant methodological flaws and a lack of controls.” That is the complete human evidence base as of 2026.
The 2025 narrative review from the University of Utah in Current Reviews in Musculoskeletal Medicine reached the same conclusion: BPC-157 demonstrates potential benefits for musculoskeletal healing in preclinical models, but the evidence does not support clinical use in humans. In other words, the jump from “works in rats” to “works in humans at this dose” has not been made – and it may never be, if independent human trials are not funded and conducted.
The IBD Human Trials – What They Actually Show
Some sources in the fitness community cite Sikirić lab papers claiming that BPC-157 was tested in human trials for inflammatory bowel disease under study names like PL-10 and PL 14736. These limited phase II trials originate primarily from one research group. They do not appear in major independent clinical trial registries under external review, and the fitness community’s extrapolation from IBD results to musculoskeletal recovery involves a significant inferential leap that the published literature does not support.
What Is TB-500 and How Does It Differ from BPC-157?
TB-500 is a synthetic peptide derived from thymosin beta-4, a protein the body naturally produces that plays a role in cell migration, wound healing, and tissue repair. TB-500 is specifically a fragment of the full thymosin beta-4 molecule. Its primary biochemical mechanism is actin sequestration – it binds G-actin monomers at the LKKTET sequence with a binding constant of approximately 0.5 μM, maintaining a cytoplasmic reserve of actin available for rapid cell migration and cytoskeletal reorganization.
TB-500 Evidence and Current Status
The 2026 American Journal of Sports Medicine review describes TB-500 this way: “TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports.” That summary is precise and accurate. TB-500 has a sound theoretical basis in its known biochemical mechanism.
Its preclinical data, particularly around wound healing and angiogenesis, is supportive. What it does not have is any published controlled human trial data demonstrating safety or efficacy at the doses circulating in the fitness community.
TB-500 is often used alongside BPC-157 in fitness communities – a practice sometimes called “stacking.” In the absence of human pharmacokinetic data for either compound individually, combining two experimental compounds compounds the unknown risk profile in ways that no peer-reviewed data can currently characterize.
“While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.”
– Mayfield, Bolia et al., Keck Hospital of USC – American Journal of Sports Medicine, 2026
Key Differences Between BPC-157 and TB-500
BPC-157 and TB-500 are different compounds with different mechanisms. BPC-157 operates primarily via the eNOS/angiogenesis pathway and has a larger published study base. TB-500 operates via actin sequestration and cell migration.
Both have been studied for similar outcomes – tissue repair, reduced inflammation, accelerated healing – but they are pharmacologically distinct. Treating them as interchangeable is inaccurate.
The Single-Lab Problem Nobody Talks About
Here is a detail that virtually no fitness article covers: a significant proportion of the BPC-157 animal study literature originates from a single research group – the Sikirić lab in Croatia. This is a meaningful scientific concern. Independent replication is the backbone of scientific validity.
When the evidence base for a compound is heavily concentrated in publications from one lab, the risk of publication bias, methodological idiosyncrasies, and non-replicable results increases substantially.
Why Lab Concentration Matters for Evidence Quality
This is not an accusation of fraud. The Sikirić group’s work has been published in peer-reviewed journals, and some of their findings have been cited by independent researchers. However, when you read a claim like “BPC-157 has been shown in dozens of studies to accelerate healing,” it is worth asking: how many of those studies are from independent labs that ran the protocol without the original researchers involved?
For BPC-157, the answer is: not many. The 2025 University of Utah narrative review explicitly flagged this as a limitation of the evidence base.
The 2026 editorial in Arthroscopy from military physicians at Brooke Army Medical Center noted that despite “exponential growth of the multi-billion-dollar therapeutic peptide industry,” the orthopaedic literature on clinical use remains “scarce.” Market growth does not equal scientific validation. Those two things move on entirely separate tracks.
“Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury. However, this has not slowed the recent exponential growth of the multi-billion-dollar industry.”
– DeFoor & Dekker, Brooke Army Medical Center / U.S. Air Force Academy – Arthroscopy, 2024
What Independent Replication Would Require
For BPC-157 to progress from “interesting preclinical compound” to “clinically recommended tool,” it would need independent animal replication from multiple labs, followed by properly controlled phase I/II human trials establishing dose-ranging, pharmacokinetics, and safety. None of that has occurred. As of May 2026, the compound remains where it has been for years: extensively studied in one lab’s animal models, anecdotally used by thousands of people online, and officially categorized by every regulatory and anti-doping body as unapproved and prohibited.
What Huberman Actually Said – Including the Caveats
Andrew Huberman covered peptide therapeutics on his April 2024 podcast episode. That episode has become the single most-cited justification in fitness communities for using BPC-157. There is a problem: most people citing him leave out the caveats.
Here is what Huberman’s actual position was.
The Endorsement That Wasn’t
Huberman acknowledged the animal-study data as “enticing” and noted that the proposed mechanisms are scientifically plausible. He did not, however, recommend BPC-157 for use by the general public. He specifically stated that “there are essentially no clinical trials and few human studies,” which he cited as the primary reason for caution.
His framing was exploratory – he walked through the science while repeatedly noting what the science does not yet establish.
More critically, Huberman flagged a specific safety concern that most summaries omit entirely: the VEGF mechanism. BPC-157’s angiogenic effects involve increased vascular endothelial growth factor signaling. In a healthy tissue context, increased blood vessel formation supports healing.
In a cancer context – or in someone with undetected precancerous cells – increased angiogenesis could theoretically support tumor growth by enhancing blood supply. Huberman explicitly recommended against use for anyone concerned about or predisposed to cancer.
The Dosing Problem
The dosing figures that circulate in fitness communities – commonly reported as 300–500 micrograms subcutaneously, two to three times per week, for eight weeks – were referenced in the Huberman episode based on anecdotal community protocols. These figures do not come from peer-reviewed human trials. No human dose-ranging study for BPC-157 has been published.
Attributing these numbers to “clinical guidance” or even to Huberman as endorsement is inaccurate. They are community-sourced protocols with no validated safety data behind them.
FDA Status, WADA Ban, and the Research Chemical Gray Area
The legal and regulatory picture for BPC-157 and TB-500 is unambiguous in one direction and genuinely complex in another. Understanding the difference matters if you are a competitive athlete, a person considering personal use, or simply someone who wants an honest answer to what are peptides from a legal standpoint.
The FDA’s Position on BPC-157
The FDA has stated clearly that BPC-157 is an unapproved new drug with no legal basis for sale or pharmaceutical compounding. In a warning letter to Warrior Labz, the agency cited BPC-157 products as “unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.” Separately, the FDA has confirmed there is no current legal basis for compounding pharmacies to use BPC-157 under the 503A framework.
You can review the FDA’s current 503A Bulk Drug Substances page at FDA.gov for the current status.
That regulatory picture may change. According to the Federal Register, the FDA’s Pharmacy Compounding Advisory Committee has a scheduled meeting on July 23–24, 2026 specifically to evaluate whether BPC-157 and TB-500 should be added to the 503A Bulks List – which would permit licensed compounding pharmacies to use them. The outcome is unknown.
This is the first time either compound has been formally considered for any pathway to legal compounding, and no fitness or health publication currently covers this development.
WADA and Competitive Athletes
BPC-157 was added to the WADA Prohibited List in 2022 under S0: Non-Approved Substances. It is prohibited at all times – in-competition and out. There are no Therapeutic Use Exemptions.
TB-500 and thymosin beta-4 are also prohibited under S0 and S2 (Peptide Hormones, Growth Factors). Per the USADA, the ban covers any competitive athlete in a WADA-compliant sport.
This is not limited to professional athletes. Recreational competitive athletes in powerlifting, CrossFit, obstacle racing, and amateur boxing – all of which have anti-doping policies aligned with WADA – are subject to the same prohibition. A positive test can result in disqualification, suspension, and public sanction.
Most fitness articles note the professional athlete ban in a footnote and fail to explain that the amateur competitive athlete population faces the same consequences.
The “Research Chemical” Gray Area
BPC-157 and TB-500 are widely sold online under the “research chemical” label. This label exploits a regulatory gray area: compounds sold exclusively for in-vitro or animal research purposes are not required to have the same regulatory approval as human pharmaceuticals. However, the FDA has explicitly stated that using these compounds in humans – regardless of how the seller labels them – still constitutes use of an unapproved drug.
The “not for human use” label on a vial is the seller’s legal hedge, not a legal clearance for the buyer. The USADA advisory on BPC-157 makes this distinction clearly.
BPC-157 vs. TB-500 vs. Creatine: An Evidence Comparison
Placing BPC-157 and TB-500 next to creatine monohydrate makes the evidence gap concrete. Creatine has decades of controlled human trials behind it. Peptides have rodent models and one methodologically flawed case series.
That comparison is not a promotion of creatine – it is a calibration of where the science actually sits.
BPC-157
- What it is: Synthetic 15-amino-acid peptide derived from gastric protein
- Mechanism: eNOS activation, angiogenesis, vasomotor tone modulation
- Animal evidence: Extensive – tendon, muscle, wound healing in rodent models
- Human evidence: One small case series with significant methodological flaws
- FDA status: Unapproved new drug – no legal basis for human use or compounding
- WADA status: Prohibited at all times under S0 – no TUE available
- Key risk: VEGF-mediated angiogenesis may be problematic in cancer-predisposed individuals
TB-500
- What it is: Synthetic fragment of thymosin beta-4, a naturally occurring protein
- Mechanism: G-actin sequestration, cell migration, cytoskeletal reorganization
- Animal evidence: Supportive – wound healing and angiogenesis in preclinical models
- Human evidence: None published for orthopaedic or sports contexts
- FDA status: Unapproved new drug – same framework as BPC-157
- WADA status: Prohibited under S0 and S2 – no TUE available
- Key risk: No human dose-ranging data; often stacked with BPC-157, compounding unknowns
Creatine Monohydrate
- What it is: Naturally occurring compound synthesized from amino acids glycine and arginine
- Mechanism: Replenishes phosphocreatine stores for ATP regeneration during high-intensity effort
- Animal evidence: Extensive – also replicated in humans
- Human evidence: Hundreds of controlled human trials across decades
- FDA status: Generally recognized as safe (GRAS) – legal dietary supplement
- WADA status: Not prohibited – legal in all competitive sports
- Key risk: None at standard doses; well-characterized safety profile
Sources: WADA Prohibited List; USADA – BPC-157 Advisory; FDA 503A Bulk Drug Substances
Mistakes to Avoid When Evaluating Peptide Claims
The information environment around peptides is noisy. Many claims circulating in fitness communities – on Reddit, in Discord servers, on podcast clips – are either overstated or simply incorrect. Here are the most common errors in how people evaluate what are peptides and what they can do.
Mistake 1: Treating Animal Data as Proof of Human Effect
Animal-to-human translation fails more often than it succeeds in pharmaceutical research. The compound history of pharmacology is full of drugs that performed brilliantly in rodent models and then failed in human trials – or worse, turned out to be harmful. The fact that BPC-157 shows consistent tissue repair effects in rat tendon models is a legitimate reason to fund human research.
It is not a legitimate basis for concluding that it will work the same way in your knee at 300 micrograms subcutaneously.
Mistake 2: Assuming “Natural Origin” Means Safe
BPC-157 is derived from a sequence found in human gastric juice. TB-500 mirrors a naturally occurring protein. Neither of these facts establishes safety at therapeutic doses.
Insulin is naturally occurring. Botulinum toxin comes from a bacterium. Many of the most dangerous substances in pharmacology have natural origins.
Dose, concentration, route of administration, and individual variation all determine safety – not origin.
Mistake 3: Misreading the “Research Chemical” Label
Products sold as research chemicals are not legal for human use under FDA interpretation. The FDA’s own enforcement actions – including against Warrior Labz – make this explicit. Buying a vial labeled “not for human use” does not place you outside FDA jurisdiction if you inject it.
It transfers legal risk from the seller to the buyer in a specific legal context, but it does not make the use lawful.
Mistake 4: Citing Huberman as Endorsement Without the Caveats
Huberman is a credible science communicator. His April 2024 peptide episode is worth listening to in full – with emphasis on the parts where he specifically flags the lack of human data and the VEGF cancer concern. If someone in your gym cites “Huberman said it works,” ask them to summarize what Huberman said about the absence of clinical trial evidence and the cancer risk.
The full picture matters.
Mistake 5: Skipping Foundational Recovery Before Exploring Experimental Options
The training community’s enthusiasm for peptides often correlates with gaps in foundational recovery: inconsistent sleep, suboptimal protein intake, poor stress management. Before considering experimental injectables, treating your body as your most important asset starts with the fundamentals that have human clinical data – sleep, strength training, nutrition, and proven supplementation like creatine.
These are not less exciting. They are more proven.
Frequently Asked Questions
What are peptides in simple terms?
Peptides are short chains of amino acids – smaller than proteins – that act as signaling molecules in the body. Your body naturally produces thousands of them to regulate processes like hormone release, tissue repair, and inflammation. The peptides discussed in fitness contexts are synthetic versions designed to amplify those natural signals.
Is BPC-157 legal to buy in the United States?
BPC-157 is sold legally in the U.S. as a “research chemical” for laboratory use, but the FDA has explicitly stated there is no legal basis for its sale or compounding for human use. Buying it as a research chemical is one thing; injecting it is treated by the FDA as using an unapproved drug. That status is up for formal review at the FDA’s July 2026 PCAC meeting.
What does BPC-157 actually do?
In animal models, BPC-157 has been shown to promote angiogenesis, activate the eNOS pathway, enhance growth hormone receptor expression in tendon fibroblasts, and accelerate wound healing. At the mechanistic level, it primarily stimulates blood vessel formation and modulates nitric oxide signaling.
In humans, there is one small case series with significant methodological limitations. No controlled human trials have been published for orthopaedic or sports recovery uses.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protein sequence, operating primarily via the eNOS and angiogenesis pathway. TB-500 is a synthetic fragment of thymosin beta-4 that works through G-actin sequestration and cell migration. Both are studied for tissue repair, but they have distinct mechanisms and separate evidence bases.
Will peptides get me banned from sports competition?
Yes – if you compete in any WADA-compliant sport. BPC-157 was added to the WADA Prohibited List in 2022 under S0: Non-Approved Substances, and TB-500 is banned under both S0 and S2. Both are prohibited at all times with no Therapeutic Use Exemptions.
This applies to recreational competitive athletes in powerlifting, CrossFit, obstacle racing, and other tested amateur sports, not only professionals.
What did Huberman say about BPC-157?
In his April 2024 episode on peptide therapeutics, Huberman acknowledged interesting animal-study evidence while stating clearly that “there are essentially no clinical trials and few human studies.” He flagged the VEGF mechanism as a potential cancer risk for predisposed individuals and recommended against use for anyone concerned about cancer. His position was exploratory, not an endorsement.
Why does it matter that most BPC-157 research comes from one lab?
Scientific credibility depends on independent replication. When a significant proportion of the evidence for a compound comes from a single research group, the risk of non-reproducible results is higher. Independent replication across multiple labs – which has not occurred at scale for BPC-157 – is a standard requirement before a compound is considered ready for clinical trials.
Are there any FDA-approved peptides?
Yes – many. Insulin, GLP-1 agonists (like semaglutide/Ozempic), tesamorelin, and numerous other peptide-based drugs are FDA-approved. The approval status reflects completed clinical trials demonstrating safety and efficacy.
BPC-157 and TB-500 have not gone through that process, which is why they carry a different legal and risk status than approved peptide drugs.
What is the FDA doing about peptides in 2026?
The FDA’s Pharmacy Compounding Advisory Committee has a meeting scheduled for July 23–24, 2026 to evaluate whether BPC-157 and TB-500 should be added to the 503A Bulks List – which would allow licensed compounding pharmacies to use them in custom formulations. The outcome is not predetermined. This is the first formal review of either compound for any compounding pathway.
Should I use BPC-157 or TB-500?
That is a medical decision, not a content decision – and this article is not medical advice. What this article can tell you is that neither compound has sufficient human evidence for a clinical recommendation, neither is FDA-approved, and both will get you banned from any WADA-tested sport. Anyone considering use should consult a physician, review the current FDA 503A status, and understand that the experimental risk is entirely unquantified by human trial data.
What are the best-evidenced recovery supplements instead?
Creatine monohydrate remains the most validated recovery supplement with the deepest human clinical evidence base. Nutricost Creatine Monohydrate is what Randal uses – it is third-party tested, micronized for easy mixing, and priced for consistent daily use.
Combined with optimized sleep, EPA/DHA omega-3s for inflammation modulation, and a well-structured training program, the evidence-backed approach to recovery outperforms any experimental injectable in terms of the quality of the data behind it. That is not a conservative argument – it is a scientific one.
What other peptides are people using in 2026?
Beyond BPC-157 and TB-500, the fitness community discusses CJC-1295 combined with ipamorelin (a growth hormone secretagogue stack), GHK-Cu (a copper peptide studied for skin and wound healing), and tesamorelin (an FDA-approved peptide for HIV-related lipodystrophy that is sometimes used off-label). Of these, the CJC-1295/ipamorelin stack has no published controlled human orthopaedic data – only a murine model study – and is also prohibited under WADA S2.
How I Know This
I have been training seriously for three years, six days a week, alongside a best friend who is a marine veteran. That experience has given me a practical education in what actually drives recovery – and a healthy skepticism for anything that promises to shortcut the fundamentals. When peptides started coming up consistently in conversations at the gym and in podcast circles, I started researching them the way I research everything: primary sources first, community claims second.
What I found is that the gap between what the research actually says and what people claim it says is wide. The animal data for BPC-157 is real. The human evidence is almost nonexistent.
The single-lab concentration problem is rarely mentioned. The FDA’s active 2026 regulatory review is completely absent from fitness coverage. I built the research for this article from peer-reviewed sources in the American Journal of Sports Medicine, Scientific Reports, and Current Reviews in Musculoskeletal Medicine – not from podcast clips or Reddit threads.
The point is not to dismiss these compounds. The point is to give you what the evidence actually supports, so you can decide what that means for your training.
The Bottom Line
What are peptides, when you strip the hype? Biologically interesting compounds with real preclinical data and almost no validated human evidence. BPC-157 and TB-500 have a significant single-lab concentration problem, a clear FDA prohibition on human use, and a WADA ban that applies to any competitive athlete.
The July 2026 FDA compounding review may change part of that picture – but it will not conjure the human clinical trial data that does not exist.
The pattern at Break The Ordinary is consistent: build your recovery stack on what has human evidence first. Disciplined systems and foundational habits outperform experimental shortcuts because the data supports them – not because they sound respectable.
If peptides eventually earn that validation through rigorous human trials, this article will be updated. Until then: promising, but unproven.
The goal at BTO is to give you a clear picture so you can make an intelligent decision – not the loudest pitch in the room.
If you want to build a recovery and performance foundation with evidence behind every element, start with what creatine actually does and why the science is airtight. That is the right baseline before evaluating anything more experimental.